Barclays’s CRISPR Therapeutics CRSP Stock Holding History

Barclays’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.19M	Buy	+25,000	New	+$1.32M	﹤0.01%	2652
2024 Q4	–	Sell	-30,000	Closed	-$1.41M	–	5307
2024 Q3	$1.41M	Sell	30,000 -84,000	-74%	-$4.26M	﹤0.01%	3127
2024 Q2	$6.16M	Buy	114,000 +87,000	+322%	+$5.03M	﹤0.01%	1425
2024 Q1	$1.84M	Sell	27,000 -25,000	-48%	-$1.79M	﹤0.01%	2640
2023 Q4	$3.26M	Buy	+52,000	New	+$2.87M	﹤0.01%	2491
2021 Q1	–	Sell	-2,500	Closed	-$383K	–	4767
2020 Q4	$383K	Buy	+2,500	New	+$295K	﹤0.01%	3401
2018 Q2	–	Sell	-34,700	Closed	-$1.59M	–	7007
2018 Q1	$1.59M	Buy	+34,700	New	+$1.43M	﹤0.01%	2715

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barclays's CRSP Position: Q1 2026 in Review

Barclays reduced its CRISPR Therapeutics (CRSP) stake by 87% in Q1 2026, selling an estimated $11.5M and leaving 32,254 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2515.

Barclays first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $23.2M in Q3 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Barclays held 32,254 shares of CRISPR Therapeutics worth $1.53M as of Q1 2026.
Barclays sold 217,734 CRISPR Therapeutics shares in Q1 2026, an estimated $11.5M.
CRISPR Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2515 holding.
Barclays first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
Barclays's CRISPR Therapeutics position peaked at $23.2M in Q3 2023.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.